1-(3-溴-2-甲基苯基)哌啶 | 1020180-10-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(3-溴-2-甲基苯基)哌啶
• 英文名称: 1-(3-bromo-2-methylphenyl)piperidine
• 英文别名: 1-(3-Bromo-2-methylphenyl)piperidine
• CAS: 1020180-10-2
• 化学式: C₁₂H₁₆BrN
• 分子量: 254.17
• InChiKey: MPZXDGINAXSLIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  哌啶 、 2,6-二溴甲苯 在 tris-(dibenzylideneacetone)dipalladium(0) R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 3.5h， 以84%的产率得到1-(3-溴-2-甲基苯基)哌啶
  参考文献：
  名称：

  Palladium-catalyzed monoamination of dihalogenated benzenes

  摘要：

  The palladium-catalyzed monoamination of symmetric dibromobenzenes can be performed using a catalyst based on Pd(2)dba(3) and BINAP in the presence of NaO(t-Bu). The analogous transformation of non-symmetric bromoiodobenzenes is most effectively performed with Xantphos as the ligand, while reactions with BINAP were non-selective. These transformations can be scaled uneventfully to >10 g quantities. They do not require drybox or Schlenk techniques, and all reagents are weighed out in air. The resulting monobromoanilines are versatile intermediates for further synthetic transformations. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.01.070

文献信息

• SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20160257657A1

  公开（公告）日：2016-09-08

  A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R 20 —(Z) b —(Y) c —(R 21 ) a —(X) d —R 22 —R 23 wherein R 20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(═O), —S(═O)(═O)—, or NR 10 , wherein R 10 is H or alkyl; R 21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(═O)—, —S(═O)(═O)—, or —N(H)C(═O)—; R 22 includes at least one divalent amino radical; R 23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.

  根据公式I，化合物或其药学上可接受的盐或酯，其中R20为芳基，取代芳基，杂环芳基，取代杂环芳基，杂环烷基，取代杂环烷基，烷氧基，芳基氧基，含硫基或含硒基；Z为烷二基，取代烷二基，环烷二基或取代环烷二基；Y为S，O，S(═O)，—S(═O)(═O)—或NR10，其中R10为H或烷基；R21为烷二基，取代烷二基，环烷二基，取代环烷二基，烯丙基，取代烯丙基，烯三基或取代烯三基；X为—C(═O)—，—S(═O)(═O)—或—N(H)C(═O)—；R22至少包括一个二价氨基基团；R23为芳基，取代芳基，杂环芳基，取代杂环芳基，杂环烷基，取代杂环烷基，烷氧基，芳基氧基，含硫基或含硒基；a、b、c和d独立地为0或1。
• COMPOUNDS FOR TREATING PROSTATE CANCER
  申请人：UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US20160264540A1

  公开（公告）日：2016-09-15

  A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: R 20 —(Z) b —(Y) c —(R 21 ) a —X—R 22 -R 23 wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, or NR 10 , wherein R 10 is H or alkyl; R 21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(=0)- or —S(=0)(=0)-; R 22 is a moiety that includes at least one divalent amino radical; R 23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; a is 0 or 1; b is 0 or 1; and c is 0 or 1; provided that if X is —C(=0)- then Y is not S.

  化合物，或其药学上可接受的盐或酯，其具有公式I：R20—(Z)b—(Y)c—(R21)a—X—R22-R23，其中R20是芳基，取代芳基，杂环芳基，取代杂环芳基，杂环烷基，取代杂环烷基，烷氧基，芳氧基，含硅基团，含硼基团，含膦基团，氨基，含硫基团，含硒基团，卤素或含硝基团；Z是烷二基，取代烷二基，环烷二基或取代环烷二基；Y是S，O或NR10，其中R10是H或烷基；R21是烷二基，取代烷二基，环烷二基，取代环烷二基，烯二基，取代烯二基，烯三基，取代烯三基；X是—C（=0）-或—S（=0）（=0）-；R22是至少包含一个双价氨基基团的基团；R23是芳基，取代芳基，杂环芳基，取代杂环芳基，杂环烷基，取代杂环烷基，烷氧基，芳氧基，含硅基团，含硼基团，含膦基团，氨基，含硫基团，含硒基团，卤素或含硝基团；a为0或1；b为0或1；c为0或1；但如果X是—C（=0）-，则Y不是S。